Anthera Pharmaceuticals, Inc. (ANTH)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jul 23, 2025, 8:00 PM EDT
Anthera Pharmaceuticals Company Description
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.
It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.
The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Anthera Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | John Thompson |
Contact Details
Address: The Pennzoil Building Houston, Delaware 77002 United States | |
| Phone | 410 350 1839 |
| Website | anthera.com |
Stock Details
| Ticker Symbol | ANTH |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US03674U3005 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Paul F. Truex M.B.A. | Executive Chairman |
| May Liu CPA | Senior Vice President of Finance and Administration and Principal Accounting Officer |
| Dr. Paul Adams Ph.D. | Senior Vice President of Global Regulatory Affairs and Compliance |
| Joshua Caldwell | Chief Liquidating Officer |